- Mission [1]
- FDA’s strategic priorities in responding to the public health challenges of the 21st century are to advance regulatory science
and innovation; strengthen the safety and integrity of the global supply chain; strengthen compliance and enforcement activities
to support public health; expand efforts to meet the needs of special populations; advance medical countermeasures and emergency
preparedness; advance food safety and nutrition; promote public health by advancing the safety and effectiveness of medical
products; establish an effective tobacco regulation, prevention, and control program; and manage for organizational excellence
and accountability. The Pulmonary-Allergy Drugs Advisory Committee supports FDA's strategic priorities by reviewing and evaluating
available data concerning the safety and effectiveness of marketed and investgational human drug products for use in the treatment
of pulmonary disease and diseases with allergic and/or immunologic mechanisms and makes appropriate recommendations to the
Commissioner of Food and Drugs. This supports the development of safe and effective new medical technologies, and advances
the status of the Agency as a science-based and science-led regulatory agency, providing global leadership in the protection
of public health.
|
